Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137

Site search

Correspondence address
310 Mira Street, Stavropol, Russia, 355017

+7 8652 352524; +7 8652 353229.

+7 8652 352524.


Pharmacokinetics of dornase alpha in cystic fibrosis in childhood and adolescence

[Cystic fibrosis]
Yulia Alexandrovna Kondakova; Elena Ivanovna Kondratieva; Svetlana Viktorovna Kostyuk; Elizaveta Sergeevna Ershova; Anna Yuryevna Voronkova; Victoria Davidovna Sherman; Vera Vladislavovna Shadrina; Sergey Kensarinovich Zyryanov;

A study of the nuclease activity in the plasma of children and adolescents with cystic fibrosis (CF) during therapy with Dornase alpha was carried out. The level of nuclease activity was measured in 35 patients after inhalation of Dornase alpha. An increase in the level of nuclease activity of blood plasma after inhalation of Dornase alpha by patients with cystic fibrosis was obtained. High variability was observed in the dynamics of changes in the level of nuclease activity during therapy with the inhaled drug Dornase alpha. According to the period of reaching the peak level of nuclease activity after inhalation of the drug (Tmax), the patients were divided into 4 groups: Tmax 1.5 hours (1 group), Tmax 3.0 hours (2 group), Tmax 4,5 hours (3 group), Tmax 6.0 hours (4 group). The change of the area under the curve (AUC) «nuclease activity – time» (ng•h/ml) in 88.59 % of cases and the PK parameter – peak nuclease activity (Cmax, ng/ml) in 89.17 % is determined by the BMI parameter (p<0.0001). Higher AUC values of nuclease activity – time (ng•h/ml) in girls were obtained. Significantly lower values of AUC «nuclease activity – time» (ng•h/ml) and Cmax, ng/ml were found in patients who received inhaled glucocorticosteroids
(IGCS) in therapy (p<0.05). The level of nuclease activity during inhalation of Dornase alfa in patients with CF depends on gender, BMI and IGCS therapy, which should be taken into account when prescribing this drug. The inhalation time can be selected according to the possibilities of the patient’s daily routine.


1. National consensus «Cystic fibrosis: definition, diagnostic criteria, therapy». (Coordinators: Kapranov N. Y., Kondratieva E. Y., Kashirskaya N. Yu.). Meditsinskaya genetika. – Medical Genetics. 2016;11:108-109. (In Russ.).
2. Yang C., Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database of Systematic Reviews 2018, Issue 9.Art. No.:CD001127. https://doi.org/10.1002/14651858.CD001127.pub3
3. Voronkova A. Yu. Clinical efficacy and safety of dornase alpha in the treatment of bronchopulmonary process in children with cystic fibrosis. Avtoref. dis. ... kand. med. nauk. Moscow, 2004. (In Russ.).
4. Ranucci R. Cell-Free DNA: Applications in Different Diseases. Methods in Molecular Biology (Clifton, N. J.). 2019;1909:3-12. https://doi.org/10.1007/978-1-4939-8973-7_1
5. Kostyuk S. V., Kon’kova M. S., Ershova E. S., Kondakova Yu. A., Budzinskiy R. M. [et al.]. The effect of extracellular DNA and plasma nuclease activity on the course of cystic fibrosis. Sibirskoe medicinskoe obozrenie. – Siberian Medical Review. 2019;(2):37-46. (In Russ.)]. https://doi.org/10.20333/2500136-2019-2-37-46
6. Emala C. W. Pulmonary Pharmacology. Pharmacology and Physiology for Anesthesia. 2019;613-628. https://doi.org/10.1016/b978-0-323-48110-6.00030-2
7. Daan J. A. Crommelin, Robert D. Sindelar, Bernd Meibohm. Pharmaceutical Biotechnology: Fundamentals and Applications. Springer Nature Switzerland AG 2019. https://doi.org/10.1007/978-3-030-00710-2
8. Miller M. R., Hankinson J., Brusasco V., Burgos F., Casaburi R. [et al.]. Standardisation of spirometry. Series «ATS/ERS task force: standardisation of lung function testing». Eur. Respir. J. 2005;26:319-338. https://doi.org/10.1183/09031936.05.00034805
9. Pellegrino R., Viegi G., Brusasco V., Crapo R. O., Burgos F. [et al.]. Interpretative strategies for lung function tests. Series «ATS/ERS task force: standardisation of lung function testing». Eur. Respir. J. 2005;26:511-522. https://doi.org/10.1183/09031936.05.00035205
10. Batchelor H. K, Marriott J. F. Paediatric pharmacokinetics: key considerations. Brit. J. Clin. Pharmacol. 2015;79(3):395-404. https://doi.org/10.1111/bcp.12267
11. Voronkova A. Y., Kondratyeva E. I., Sherman V. D., Polyakov D. P., Petrov A. S. [et al.]. Dornasum alfa in treatment of patients with cystic fibrosis. Pediatriya. Zhurnal im. G. N. Speranskogo. – Pediatrics. Journal them G. N. Speransky. 2019;98(6):111-117. (In Russ.)]. https://doi.org/10.24110/0031-403X-2019-98-6-111-117
12. Chernyak A. V., Krasovsky S. A., Gorinova Y. V., Voronkova A. Yu., Mukhina M. A. Respiratory function and its connection with nutritional and microbiological status of patients with cystic fibrosis. Prakticheskaya pul’monologiya. – Practical pulmonology. 2018(1):43-50. (In Russ.).
13. Kondratieva E. I., Krasovskiy S. A., Voronkova A. Y., Chernyak A. V., Sherman V. D. [et al.]. Lung function of children and adolescents with cystic fibrosis in the Russian Federation. Pediatriya. Zhurnal im. G. N. Speranskogo. – Pediatrics. Journal them. G. N. Speransky. 2016;95(4):136-142. (In Russ.).
14. Dwyer M. A., Huang A. J., Pan C. Q., Lazarus R. A. Expression and characterization of a DNase I-Fc fusion enzyme. J. Biol. Chem. 1999;274(14):9738-9743. https://doi.org/10,1074/jbc.274.14.9738
15. Kondratyeva E. I., Kondakova Yu. A., Kostyuk S. V., Ershova E. V., Zyryanov S. K. [et al.]. Extracellular DNA and plasma nuclease activity effect on the course of the microbial inflammatory process in the respiratory tract in cystic fibrosis. J. Bioinform. Genom. 2018;3(8):2530-1381. (In Russ.).

Keywords: cystic fibrosis, pediatrics, nuclease activity, Dornase alpha

Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy